Segall Bryant & Hamill LLC Trims Stock Holdings in Celldex Therapeutics, Inc. $CLDX

Segall Bryant & Hamill LLC lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 32.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 346,919 shares of the biopharmaceutical company’s stock after selling 167,612 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Celldex Therapeutics were worth $11,004,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of CLDX. Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 39.3% during the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after acquiring an additional 2,279,605 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Celldex Therapeutics by 781.0% in the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $35,612,000 after acquiring an additional 1,551,354 shares during the last quarter. Braidwell LP boosted its position in shares of Celldex Therapeutics by 214.0% during the 4th quarter. Braidwell LP now owns 1,858,109 shares of the biopharmaceutical company’s stock worth $50,466,000 after purchasing an additional 1,266,420 shares during the period. Elmind Capital LP purchased a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $23,493,000. Finally, State Street Corp increased its holdings in Celldex Therapeutics by 19.5% in the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock valued at $92,282,000 after purchasing an additional 555,579 shares during the last quarter.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $38.06 on Monday. The firm has a market cap of $2.99 billion, a PE ratio of -8.93 and a beta of 0.87. Celldex Therapeutics, Inc. has a 52-week low of $19.72 and a 52-week high of $40.30. The company’s 50 day moving average is $34.30 and its two-hundred day moving average is $31.07.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.80 million. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CLDX. Morgan Stanley cut their target price on Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. Guggenheim raised their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald cut their price objective on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Canaccord Genuity Group decreased their target price on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, HC Wainwright restated a “buy” rating and set a $42.00 target price on shares of Celldex Therapeutics in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.62.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.